BOISE, ID – Idaho Attorney General Raúl Labrador has announced a multistate settlement in principle with Mylan Inc., a pharmaceutical company now part of Viatris, for its alleged role in fueling the opioid crisis. The proposed agreement would secure up to $335 million in payments nationwide, with funds directed toward efforts to combat opioid misuse and support recovery programs.
According to Labrador’s office, the attorneys general involved in the case allege that Mylan deceptively marketed its opioid products—including fentanyl patches, oxycodone, hydrocodone, and buprenorphine—over a span of several years beginning in 2005. Despite evidence that these drugs, particularly the fentanyl patches, were susceptible to abuse, the company is accused of promoting them as having a lower risk of misuse.
The complaint also states that Mylan targeted physicians in its marketing efforts, which allegedly contributed to widespread overprescribing and the diversion of opioid medications into illegal drug markets.
The proposed settlement has not yet been finalized. Once approved, funds from the agreement will be distributed among participating states to support treatment, prevention, and education initiatives related to the ongoing opioid crisis.
Mylan has not admitted to any wrongdoing as part of the settlement.
Additional information about the distribution of funds or Idaho’s share of the settlement was not immediately available.
For further inquiries, the Attorney General’s Office directed media to contact Damon Sidur at damon.sidur@ag.idaho.gov.